Dan Skovronsky knows what a good drug of obesity does.
As head of scientific officer in Eli LillyHe has already done it once with the company's weekly shot, Zepbound. He is trying to do it again with a more convenient daily pill, then repeat the feat with a photo that could be even more powerful than Zepbound. And that does not tell the other obesity drugs in Lilly's tests in clinical trials.
Skovronsky said that the race to create the next great drug is no longer just about weight loss, something that more investors and analysts are beginning to say.
Carry AmgenExperimental Drug Marituro: People lost up to 20% of their body weight in a phase two study and Amgen's actions fell around 5% the day the results were published in November. Because? Investors were concerned that it was not enough to compete with Wegovy from Lilly's Zepbound and Novo Nordisk, which will have a one -year advantage.
A Zepbound injection pen of Eli Lilly & Co. organized in the Brooklyn district in New York, USA, on Thursday, March 28, 2024.
Shelby Knowles | Bloomberg | Getty images
Skovornsky sees improve the ease of use and make more powerful drugs such as two paths to move the field forward. He imagines pills like Lilly's orforgripron arriving at people around the world. He sees drugs that can offer more weight loss, possibly including Lilly's self -life, as another area with potential.
But he is more excited to see how many other health conditions, or intestinal hormone, medicines can treat. Lilly's Zepbound was recently approved to treat sleep apnea. The company is also exploring if it can deal Addiction, heart disease, inflammation and gastrointestinal conditions.
You can see the full interview for more Skovronsky information about Lilly's work in obesity and where he sees the market underway.
